Self-Management Of Asthma By Forced Oscillation Technique

NCT ID: NCT04963140

Last Updated: 2023-02-13

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

200 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-11-16

Study Completion Date

2024-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Self-management strategies for asthma, including patients engagement and adherence to personalised action plans with advice on recognizing and responding to deterioration in control with effective treatments can improve asthma outcomes and possibly reduce the risk of future exacerbations. However, the real-life evidence is that asthma control remains sub-optimal in the majority of cases, thus increasing the related socio-economic costs worldwide.

Because an increased variability of lung function remains a hallmark of poor asthma control and exacerbations, its assessment over time could contribute to the success of self-management plans. Previous studies have shown the potential of Forced Oscillation Technique (FOT) as a tool for monitoring increased variability of airway obstruction and for identifying the onset of acute deterioration of airway function.

The aim of this study is to test the hypothesis that a personalised self-management plan including FOT improves asthma control and reduces number of days with increased symptoms compared to conventional asthma treatment.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Asthma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Intervention

Intervention subjects will monitor their lung function daily by Forced Oscillation Technique (FOT) device. The embedded algorithm signals when an increased risk of exacerbation is detected and subjects shall modify their treatment based on the action plan prescribed by the study doctor at enrolment and used for the self-management of their asthma

Group Type EXPERIMENTAL

Optimized self-management of asthma

Intervention Type OTHER

Short-term increase of asthma medication (as prescribed by the study doctor at enrolment) if an increased risk of asthma exacerbations is detected by the home monitoring device

Control

Control subjects will monitor their lung function daily by Forced Oscillation Technique (FOT) device. The embedded algorithm used in the intervention arm is disabled. Subjects will follow the action plan prescribed by the study doctor at enrolment for the self-management of their asthma

Group Type SHAM_COMPARATOR

Conventional self-management of asthma

Intervention Type OTHER

Short-term increase of asthma medication (as prescribed by the study doctor at enrolment) is based on subject's self-perception of symptoms

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Optimized self-management of asthma

Short-term increase of asthma medication (as prescribed by the study doctor at enrolment) if an increased risk of asthma exacerbations is detected by the home monitoring device

Intervention Type OTHER

Conventional self-management of asthma

Short-term increase of asthma medication (as prescribed by the study doctor at enrolment) is based on subject's self-perception of symptoms

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age: 6-65 years old
* Diagnosis of persistent asthma
* Treatment level at study entry:

* For children 6-11 years: Step2 or Step3 of the GINA document
* For adolescents and adults 12-65 years: Step2 under daily low-dose inhaled corticosteroids (ICS), Step 3 or Step 4 of the GINA document
* Uncontrolled asthma (ACQ-5 \> 1.5) that, according to the physician, does not warrant an immediate step-up of the treatment
* History of moderate or severe exacerbations in the twelve (12) months prior to baseline visit

Exclusion Criteria

* Use of oral, rectal or parenteral glucocorticosteroids 30 days before enrolment
* Treatment with leukotriene receptor antagonist (LTRA)
* Treatment with maintenance and reliever therapy (SMART/MART)
* Smoking, current or previous with a history of 10 pack-years or more
* Documented COPD or other concomitant clinically important diseases or cognitive impairment that, according to the physician, may interfere with the subject's ability or safety to participate in the study
* Obesity (for subjects 6-19 years: BMI ≥ 95th percentile; for adults 20-65 years: BMI ≥ 40kg⋅m-2
* For school-age children (6-11 years old): gestational age at birth \< 37 weeks or documented bronchopulmonary dysplasia (BPD)
* Prolonged absence from home during the monitoring period (i.e. at recruitment, expected ≥3 consecutive weeks for ≥2 times during the 9- month monitoring period) Subject currently enrolled in other clinical trials related or involving the study of the respiratory system
* History of near-fatal asthma
* Women who are pregnant, nursing or intending to become pregnant during the time of the study
* Absence of health insurance coverage (applies to French centres only)
Minimum Eligible Age

6 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Restech Srl

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Woolcock Institute of Medical Research

Sydney, , Australia

Site Status NOT_YET_RECRUITING

Grenoble University Hospital

Grenoble, , France

Site Status RECRUITING

University Children's Hospital of Nancy

Nancy, , France

Site Status RECRUITING

Azienda Ospedaliero, Universitaria Meyer

Florence, FI, Italy

Site Status RECRUITING

AOU Ospedali Riuniti Ancona

Ancona, , Italy

Site Status RECRUITING

ASST Papa Giovanni XXIII

Bergamo, , Italy

Site Status RECRUITING

Istituto di Farmacologia Traslazionale (IFT) del CNR

Palermo, , Italy

Site Status NOT_YET_RECRUITING

Istituto di Farmacologia Traslazionale (IFT) del CNR

Palermo, , Italy

Site Status NOT_YET_RECRUITING

Fondazione IRCCS Policlinico S. Matteo

Pavia, , Italy

Site Status RECRUITING

Azienda Unità Sanitaria Locale di Reggio Emilia

Reggio Emilia, , Italy

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Australia France Italy

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Alessandro Gobbi, PhD

Role: CONTACT

+390236593690

Pasquale Pio Pompilio, PhD

Role: CONTACT

+390236593690

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Gregory King

Role: primary

Sam Bayat

Role: primary

Iulia Cristina Ioan

Role: primary

Enrico Lombardi

Role: primary

Maria Beatrice Bilo'

Role: primary

Gianluca Imeri, Dr

Role: primary

Stefania La Grutta

Role: primary

Giuseppina Cuttitta

Role: primary

Angelo Corsico

Role: primary

Chiara Scelfo

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

1/20

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Triple in Asthma Dose Finding
NCT02127866 COMPLETED PHASE2
Asthma in Children
NCT01286532 COMPLETED